Showing posts with label Parasitology. Show all posts
Showing posts with label Parasitology. Show all posts

11 July 2023

The Free-Living Amoeba

 

The classical taxonomic classification divided the Protozoa into four groups:

a.     Sarcodina (amoebae)

b.     Mastigophora (flagellates)

c.      Sporozoa (most parasitic protozoa)

d.     Infusoria (ciliates)

This taxonomy has been totally abandoned by the International Society of Protozoologists based on modern morphological approaches such as biochemical pathways and molecular phylogenetics (e.g., 18S rRNA sequences). The older hierarchical systems consisting of the traditional “kingdom,” “phylum,” “class,” “subclass,” “super-order,” “order,” has been replaced by a new vocabulary.

According to this new schema, the Eukaryotes have been classified into six clusters or “Super Groups,” namely:

a.     Amoebozoa

b.     Opisthokonta

c.      Rhizaria

d.     Archaeplastida

e.     Chromalveolata

f.      Excavata

The three amoebae that are dealt within this article have been classified under two Super Groups, Amoebozoa and Excavata, as follows:

a. Acanthamoeba and Balamuthia are classified under Super Group Amoebozoa: Acanthamoebidae

b. Naegleria fowleri under Super Group Excavata: Heterolobosia: Vahlkampfiidae

This schema has been proposed as the basis for future revisions.

For educational purposes, the classic phylogeny of the parasite was described here. And unlike amoeba belonging to Phylum Sarcodina that requires host to survive, parasites belonging in this group are free living (i.e., doesn’t require host to survive).


NAEGLERIA FOWLERI

Phylum Percolozoa

Subphylum Tetramitia

Order Schizopyrenida

Family Vahlkampfiidae

Genus Naegleria

Naegleria fowleri is an amphizoic amoeba, as it can survive in a free-living state in water, soil, or in the host, which can be the human central nervous system (CNS) and causes a disease known as Primary Amebic Meningoencephalitis (PAM) thus its reputation as "brain-eating amoeba."

The initial symptoms of PAM are indistinguishable from bacterial meningitis, while the symptoms of GAE can mimic a brain abscess, encephalitis, or meningitis.

The amoeboid stage is roughly cylindrical, typically around 20–40 μm in length. They are traditionally considered lobose amoebae, but are not related to the others, and unlike them, do not form true lobose pseudopods. Instead, they advance by eruptive waves, where hemispherical bulges appear from the front margin of the cell, which is clear. The flagellate stage is slightly smaller, with two or four anterior flagella anterior to the feeding groove.

Naegleria fowleri has been thought to infect the human body by entering the host through the nose when water is splashed or forced into the nasal cavity. Infectivity occurs first through attachment to the nasal mucosa, followed by locomotion along the olfactory nerve and through the cribriform plate (which is more porous in children and young adults) to reach the olfactory bulbs within the CNS. Once Naegleria fowleri reaches the olfactory bulbs, it elicits a significant immune response through activation of the innate immune system, including macrophages and neutrophils. Naegleria fowleri enters the human body in the trophozoite form. Structures on the surface of trophozoites known as food cups enable the organism to ingest bacteria, fungi, and human tissue. In addition to tissue destruction by the food cup, the pathogenicity of Naegleria fowleri is dependent upon the release of cytolytic molecules, including acid hydrolases, phospholipases, neuraminidases, and phospholipolytic enzymes that play a role in host cell and nerve destruction. The combination of the pathogenicity of Naegleria fowleri and the intense immune response resulting from its presence results in significant nerve damage and subsequent CNS tissue damage, which often result in death.

The quickest way to diagnose Naegleria fowleri infection is by microscopic examination of fresh, unfrozen, unrefrigerated cerebrospinal fluid (CSF).

Both chlorinated and salt water significantly decrease the risk of Naegleria fowleri infection due to its inability to survive in such environments. Thus, avoidance of exposure to freshwater bodies such as lakes, rivers, and ponds, especially during the summer months when the water temperature is higher.


ACANTHAMOEBA SPP.


Phylum Amoebozoa

Class Conosea

Order Centramoeba

Family Acanthamoeba


Some of the pathogenic species:

a.     Acanthamoeba castellanii

b.     Acanthamoeba culbertsoni

c.      Acanthamoeba polyphaga

d.     Acanthamoeba healyi

e.     Acanthamoeba divionensis

Diseases caused by Acanthamoeba include keratitis and granulomatous amoebic encephalitis (GAE).

Acanthamoeba keratitis (AK) is associated with trauma to the cornea or contact-lens wear and the use of amoeba–contaminated saline. Minor erosion of the corneal epithelium may occur while wearing hard or soft contact lenses, and the subsequent use of contaminated saline solution is the major risk factor for Acanthamoeba keratitis. AK is characterized by inflammation of the cornea, severe ocular pain, and photophobia, a characteristic 360o or paracentral stromal ring infiltrate, recurrent breakdown of corneal epithelium, and a corneal lesion refractory to the commonly used antibiotics. Typically, only one eye is involved; however, bilateral keratitis has also been reported. It is the MBP (mannose binding protein) that mediates the adhesion of the amoeba to corneal epithelial cells and is central to the pathogenic potential of Acanthamoeba.

A unique and characteristic feature of Acanthamoeba spp. is the presence of fine, tapering, thorn-like acanthopodia that arise from the surface of the body.

a. The trophozoites range in size from 15 to 50mm depending upon the species. They are uninucleate, and the nucleus has a centrally placed, large, densely staining nucleolus. The cytoplasm is finely granular and contains numerous mitochondria, ribosomes, food vacuoles, and a contractile vacuole. When food becomes scarce, or when it is facing desiccation or other environmental stresses, the amoebae round up and encyst.

b. Cysts are double-walled and range in size from 10 to 25mm. Cysts are uninucleate and possess a centrally placed dense nucleolus. Upon return to favourable growth conditions, the dormant amoeba is activated to leave the cyst by dislodging the operculum and reverting to a trophic form

(1)   The outer cyst wall, the ectocyst, is wrinkled with folds and ripples and contains protein and lipid.

(2)   The inner cyst wall, the endocyst, contains cellulose and hence is Periodic Acid Schiff (PAS) positive. The endocyst varies in shape: it may best ellate, polygonal, oval, or spherical.

(3)   Pores or ostioles that are covered by convex–concave plugs or opercula are present at the junction of the ectocyst and the endocyst.

In either the trophic or the cyst stage these organisms have a wide distribution in nature, and it is virtually impossible not to isolate members of this genus from soil, water, and other samples.

Acanthamoeba spp. Are ubiquitous and occur worldwide. They have been isolated from soil, fresh and brackish waters, bottled mineral water, cooling towers of electric and nuclear power plants, heating, ventilating and air conditioning units, humidifiers, Jacuzzi tubs, hydrotherapy pools in hospitals, dental irrigation units, dialysis machines, dust in the air, bacterial, fungal and mammalian cell cultures, contact-lens paraphernalia, ear discharge, pulmonary secretions, swabs obtained from nasopharyngeal mucosa of patients with respiratory complaints as well as of healthy individuals, maxillary sinus, mandibular autografts, and stool samples. In addition, several Acanthamoeba species have been isolated from the brain, lungs, skin, and cornea of infected individuals.


BALAMUTHIA MANDRILLARIS

Balamuthia mandrillaris is a free-living amoeba that is found in the soil and fresh water and is associated with Granulomatous Amoebic Encephalitis (GAE), a “brain-eating” disease both in humans and animals. Symptoms of granulomatous amebic encephalitis begin gradually. Confusion, headache, and seizures are common. People may have a low-grade fever, blurred vision, changes in personality, and problems with speaking, coordination, or vision. One side of the body or face may become paralyzed.

Balamuthia mandrillaris may cause skin sores in addition to the symptoms above. Most infected people die, usually 7 to 120 days after symptoms begin.

Possible modes of transmission of Balamuthia include inhalation and inoculation through broken skin.

Balamuthia mandrillaris, like Acanthamoeba, has only two life-cycle stages, namely the vegetative trophozoite and the dormant cyst.

a. The trophozoite is pleomorphic and measures from 12 to 60 µm (mean of 30 µm). The trophic amoebae are usually uninucleate, although binucleate forms are occasionally seen. The nucleus contains a large, centrally placed, dense nucleolus; occasionally, however, amoebae with two or three nucleolar bodies have been seen, especially in infected tissues.

b. Cysts are also uninucleate, are spherical, and range in size from 12 to 30 µm (mean of 15 µm). Cysts, when examined with a light microscope, appear to be double walled, the outer wall being wavy and the inner wall round, and pores are not seen in the wall. Ultrastructurally, however, the cyst wall has three layers:

(1)   an outer thin and irregular ectocyst,

(2)   an inner thick endocyst, and

(3)   a middle amorphous fibrillar mesocyst.

In general, Acanthamoeba spp. and Balamuthia are difficult to differentiate in tissue sections by light microscopy because of their similar morphology. However, they can be differentiated by immunofluorescence analysis of the tissue sections using rabbit anti–Acanthamoeba or anti–B–mandrillaris sera.

While Balamuthia and Naegleria share some similarities, Balamuthia is more difficult to detect. This is due to its resemblance to histiocytes under the microscope and unique culture requirements. Unlike Naegleria, Balamuthia cannot be grown on agar because it only feeds on mammalian cells and other amoebas. Furthermore, healthy individuals can be seropositive for Balamuthia antibodies due to the amoeba’s pervasive presence in the environment, while those with GAE show low titers. Additionally, cerebrospinal fluid analysis rarely demonstrates the organism, and the time course for the appearance of lesions and the onset of GAE is inconsistent. Balamuthia, unlike most of other free-living amoebae, does not feed on Gram-negative bacteria and therefore the use of non-nutrient agar coated with bacterial cultures has resulted to be ineffective for its growth.

These amoebae were normally cultured on monolayers of African green monkey kidney cells. Upon axenic cultivation, amoebae grew at various temperatures ranging from 25°C to 37°C (optimal growth at 37°C) and remained viable for up to several months, but they became smaller over time. In contrast, mammalian cultures can be used persistently as feeder cells to culture Balamuthia amoebae over longer periods, without any modifications in their general appearance. All tested cell cultures, including human brain microvascular endothelial cells (HBMEC), human lung fibroblasts, monkey kidney (E6) cells, and African green monkey fibroblast-like kidney (Cos-7) cells, supported the growth of B. mandrillaris.

20 August 2017

POLICIES ON SELECTED MICROBIOLOGICAL AND PARASITOLOGICAL DIAGNOSIS


A. REPUBLIC ACT No. 10767
An act establishing a comprehensive Philippine Plan of Action to eliminate tuberculosis as a public health problem and appropriating fund therefore


B. REPUBLIC ACT No. 9482
An act providing for the control and elimination of human and animal rabies, prescribing penalties for violation thereof and appropriating funds therefore
  

C. ADMINISTRATIVE ORDER
Rules and regulation governing the antimicrobial resistance surveillance program accreditation of bacteriology laboratories in the Philippines for the philhealth reimbursement of select antibiotics in the Philippine national drug formulary


D. ADMINISTRATIVE ORDER
Designation of the Research Institute for Tropical Medicine (RITM) as the Philippine National Influenza Center (PNIC)


E. ADMINISTRATIVE ORDER
Guidelines on the establishment of Malaria Elimination Hubs


F. ADMINISTRATIVE ORDER
Guidelines in the implementation of the Quality Assurance System of Malaria Microscopy in the PHilippines


G. ADMINISTRATIVE ORDER
Diagnosis and treatment guidelines of Capillariasis infections           

H. ADMINISTRATIVE ORDER
Guidelines in the implementation of mass treatment strategy for Schistosomiasis Control /elimination


I.  ADMINISTRATIVE ORDER
Guidelines for the implementation of the quality assurance system on direct sputum smear microscopy (dssm)


J. ADMINISTRATIVE ORDER
Guidelines on the management and control of Meningococcal Disease
  

K. ADMINISTRATIVE ORDER
Technical guidelines in the stratification of malaria endemic areas


L. ADMINISTRATIVE ORDER
Implementing guidelines on sustainable preventive and vector control measures of the malaria control program


Administrative Order No. 55 s. 2000

  
May 30, 2000


ADMINISTRATIVE ORDER
No. 55 series 2000


GUIDELINES IN THE IMPLEMENTATION OF MASS TREATMENT STRATEGY FOR SCHISTOSOMIASIS CONTROL / ELIMINATION


The Philippines is one of the world’s important endemic countries for Schistosomiasis. The disease occurs in 10 regions, 25 provinces, 183 municipalities and 1112 barangays in the country with an estimated total endemic population of 1.8 million.

Schistosomiasis has remained a public health problem for almost 6 decades since the occurrence of an epidemic in 1944, among American and Allied forces that landed in Leyte. With the present national health directional goal towards disease elimination, the Schistosomiasis Control Program of the Department of Health should implement a more aggressive strategy to attain this end (prevalence rate of <1%). Hence, Mass Drug Administration or Mass Treatment Strategy shall be implemented in all schistosomiasis endemic areas.

In coordination with the local Government Units, the Regional and Provincial Schistosomiasis Coordinators; the Provincial Based Schistosomiasis Control Teams and the National Center for Infectious Diseases shall cooperate with each other in planning and conducting the activities on schistosomiasis mass treatment strategy for the attainment of the schistosomiasis control program goal and objectives.

I.     STRATEGIES/ACTIVITIES

1. Social Mobilization and Advocacy:

a. To generate active support and encourage collaborative effort in the control / elimination of schistosomiasis, inter–sectoral coordination shall be carried out thru advocacy meetings with local government executives; school officials and teachers, various social, political and business groups; and other government and non–government organizations.

b. Continuous IEC activities as well as development and provision of IEC materials shall be implemented to sustain the community’s level of awareness.

c. Orientation and skills development training shall be conducted for service providers who will be involved in the mass chemotherapy program.

d. Barangay assemblies for advocacy and social preparation shall be undertaken prior to the conduct of mass treatment to ensure support and active participation of target public/beneficiaries.

e. Health education and communication campaign activities shall be in coordination with the Department of Education, Culture and Sports; the Philippine Information Agency; and the Public Information and Health Education Service of the Department of Health.

f.  The local government units shall be encouraged to adopt and integrate the schistosomiasis mass treatment strategy into their local health program for sustainability.

2.  Mass Treatment (Mass Drug Administration):

a. Mass treatment (treatment without the benefit of stool examination) shall be implemented country wide in all schistosomiasis endemic barangays and the population to be covered will be age 5 years old and above.

b. Praziquantrel (generic name) the drug to be used for schistosomiasis mass treatment, will be given at 40–50 mg/kg body weight and shall be taken filled stomach or after ingestion of food.

c. For individuals having body weight of 31 kg and above, praziquantrel will be applied in single dose while those with less than 31 kg body weight, the drug will be given in 2 divided doses (split dose) at 4 – 6 hours interval.

d. Treated individuals shall be observed for a few hours for possible side reaction, before allowing to leave the designated treatment centers.

e. Anti–reaction drugs must be readily available during mass treatment. Individuals with generally poor condition shall be given supportive drugs such as Vitamins and hematinics.

f. Those with history of epileptic seizure, with high blood pressure as well as with enlarge spleen or in the advance stage should be referred to the hospital for treatment.

g. Although praziquantrel has not shown to be mutagenic, teratotogenic or embryotoxic, administration of drug is not recommended for pregnant women unless immediate intervention is essential. Nursing mothers on the other hand shall not breastfeed their babies for 48 hours after praziquantrel treatment.

h. Rural Heath Physician shall be encouraged in the supervision/administration of treatment during the scheduled mass treatment.

i.  Properly trained Medical Technologists, Midwives, other health workers and paramedics maybe allowed to administer treatment provided they are under the supervision of a physician.

j.  Setting up treatment centers and scheduling of treatment can be done in the health centers, barangay halls, school and in their respective houses or any convenient designated area.

k. Praziquantrel tablets should be placed in a well–closed container protected from light.

3. Support activities (Snail Control and Environmental Modification):

a. Partnership initiatives shall be established with the Department of Public Works and Highways, Department of Agriculture, National Irrigation Administration, the community and other stakeholders for Snail Control and Environmental Modification activities, particularly infrastructure projects such as provision of sanitary toilets and safe water supply, construction of drainage systems and footbridges, and other related schistosomiasis projects.

b. Whenever resources is available, application of molluscicide will be done by the Schistosomiasis control teams in collaboration with the community concerned in areas where eradication of snails (O. hupensis quadrasi) is possible and where disease transmission is relatively high.

II.    MONITORING / EVALUATION AND SURVEILLANCE SYSTEM

1. In order to adequately assess the effect of mass treatment and guide public health for further action, monitoring/evaluation and surveillance system shall be developed.

2. Since it is not feasible to cover the entire endemic population sentinel sites for surveillance and monitoring shall be established / identified in every endemic province.

3. Well defined common indicators (e.g. prevalence, incidence, egg output per gram, snail infection rate, etc.) and comparable procedure for data collection system shall be developed, so that effect/impact of mass treatment strategy can be drawn.

4. Masterlist of the endemic population per barangay shall be established and maintained.

5. Mass treatment service statistics shall be recorded and maintained by the Schistosomiasis control teams and rural health units and shall be consolidated by the regional health offices.

6. Regional Health Offices concerned shall furnish copy of the consolidated reports to the National Center for Infectious Diseases at DOH central office.

7. Staff from the Regional Health Offices concerned and from the National Center for Infectious Diseases, shall conduct periodic monitoring and assessment on the progress of implementation.


This order superseded Administrative Order No. 6 series 1996 dated 27 February 1996.



ALBERTO G. ROMUALDEZ, JR, MD
Secretary of Health


Administrative Order No. 14-B s.1996

 May 14, 1996


ADMINISTRATIVE ORDER
No. 14–B series 1996


TECHNICAL GUIDELINES IN THE STRATIFICATION OF MALARIA ENDEMIC AREAS


A critical component of malaria control is the epidemiological assessment of malarious areas in order to document key local patterns of transmission and disease and to pinpoint priority areas for intervention. The experience gained in this type of stratification in other countries has increased the usefulness of the process in assisting malaria programs to establish operational priorities. A general sense of the focality and diversity of key variables is essential in order to determine the framework for rational stratification.


1.    DEFINITION


Stratification of the Malaria–Endemic Areas is the process of classifying the different endemic sites or localities of a particular barangay into type “A”, type “B” and type “MEPA” areas, endemic area being defined as having the malaria vector mosquito and the factors for transmission.


2.    OBJECTIVES


2.1  To establish operational priorities based on the defined criteria for stratification wherein malaria prevention and control measures will be appropriate and applicable.

2.2  To guide planners in resource allocation


3.    CRITERIA


3.1 Parasite rate of Children 10 years old and below
3.2 Terrain or Topography
3.3 Social, Economic and Cultural Conditions


4.    CHARACTERISTIC OF THE 3 TYPES BASED ON THE CRITERIA


CRITERIA
MALARIOUS A
MALARIOUS B
MALARIA
EPIDEMIC–PRONE
AREA (MEPA)
Parasite Rate
≥ 2%
High transmission
≥ 2%
High transmission
≥ 2%
Low transmission
Topography
Mountainous
Forested
Generally
Agriculturally
less developed
Forest Fringes
Foothills
Agriculturally
developed
Plains
Coastal
Any Topography
Socio–Economic
Conditions
Houses poorly constructed
Cultural Minority
Seasonal Movement
More or less stable
More or less stable


5.    GUIDELINES


5.1 This be done and updated by the Field Assistance Worker (FAW) or the Municipal Malaria Coordinator (MMC) every three (3) years

5.2 The consolidate Provincial Stratification Data should be submitted to the Malaria Control Service (MCS) before the end of the 3rd quarter of the year.

5.3 Table I illustrate the Stratification of Areas and the Appropriate Control Strategies to be implemented

TABLE 1: MALARIA CONTROL MEASURE TO BE APPLIED ACCORDING TO STRATIFIED AREA

CONTROL
STRATEGIES
STRATIFIED AREA
“A”
“B”
MEPA
1.     Early Diagnosis
And Prompt treatment
2.     Chemoprophylaxis


3.     Use of Insecticide–treated mosquito net
4.     House Spraying


5.     House Seeding
Optional
6.     Stream Clearing
Optional
7.     Personal Protection Measures
8.     Early Detection, Prevention and Control of Epidemics